

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number
WO 2004/037262 A2

(51) International Patent Classification⁷: **A61K 31/519**,
31/444, 31/4178, 31/4439, A61P 15/12, A61K 31/538,
31/501, 31/4985, 45/08, 31/4704, 31/437, 31/4427, 31/502

(74) Agents: REED, Dianne, E. et al.; Reed & Eberle LLP, 800
Menlo Avenue, Suite 210, Menlo Park, CA 94025 (US).

(21) International Application Number:
PCT/US2003/033642

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 22 October 2003 (22.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/279,039 22 October 2002 (22.10.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: VIVUS, INC. [US/US]; 1172 Castro Street,
Mountain View, CA 94040 (US).

Published:

— without international search report and to be republished
upon receipt of that report

(72) Inventors: PLACE, Virgil, A.; P.O. Box 44555, 10 Ala
Kahua, Kawaihae, HI 96743 (US). WILSON, Leland, F.;
164 East Creek Drive, Menlo Park, CA 94025 (US). DO-
HERTY, Paul, C. (deceased). HANAMOTO, Mark, S.;
3301 Haskins Drive, Belmont, CA 94002 (US). SPIVAK,
Alfred, P.; 360 Arbor Road, Menlo Park, CA 94025 (US).
GESUNDHEIT, Neil; 250 Portola Court, Los Altos, CA
94022 (US). BENNETT, Sean, R.; Apartment 2, 816
Cherry Street, Denver, CO 80220 (US).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 2004/037262 A2

(54) Title: IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION FOR ENHANCEMENT OF FEMALE SEXUAL DESIRE AND RESPONSIVENESS

(57) Abstract: An immediate release topical pharmaceutical composition is provided which is administrable on an as-needed basis to enhance female sexual desire and responsiveness. The formulation contains a Type III, Type IV, Type V, or nonspecific phosphodiesterase inhibitor as an active agent.

IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION
FOR ENHANCEMENT OF FEMALE SEXUAL DESIRE AND RESPONSIVENESS

TECHNICAL FIELD

[0001] This invention relates generally to pharmaceutical formulations and methods for enhancing female sexual desire and responsiveness. More particularly, the invention pertains to a topical pharmaceutical formulation that may be administered on an as-needed basis to enhance female sexual desire and responsiveness.

BACKGROUND

[0002] Sexual response in women is generally classified into four stages: excitement, plateau, orgasm, and resolution. Masters and Johnson, *Human Sexual Response* (Boston, MA: Little, Brown & Co., 1966). With sexual arousal and excitement, vasocongestion and muscular tension increase progressively, primarily in the genitals, and is manifested by increased blood flow, elevated luminal oxygen tension, and vaginal surface lubrication as a result of plasma transudation that saturates the fluid reabsorptive capacity of the vaginal epithelium. Sexual excitement is initiated by any of a number of psychogenic or somatogenic stimuli and must be reinforced to result in orgasm. With continued stimulation, excitement progresses in intensity into a plateau stage, from which the individual can shift into orgasm. The orgasmic stage is characterized by a rapid release from vasocongestion and muscular tension.

[0003] During the various stages of sexual response, characteristic genital and extragenital responses occur. Estrogens magnify the sexual responses; however, sexual responses may also occur in estrogen-deficient individuals. Sexual dysfunction may be due to organic or functional disturbances. For example, a variety of diseases affecting neurologic function, including diabetes mellitus and multiple sclerosis, may interrupt sexual arousal. More commonly, local pelvic disorders, such as endometriosis and vaginitis, both of which cause dyspareunia (difficult or painful coitus) may also affect a woman's sexual response. In addition, estrogen deficiency, causing vaginal atrophy and dyspareunia, is a common cause of sexual dysfunction. For a discussion of other causes of female sexual dysfunction, see, e.g., Kaplan, *The Evaluation of Sexual Disorders: Psychological and Medical Aspects* (New York: Brunner-Mazel, 1983), and Kolodny et al., *Textbook of Sexual Medicine* (Boston, MA: Little, Brown & Co., 1979).

[0004] Excitement stage dysfunction generally involves touch sensation impairment, loss of clitoral sensation, vaginal dryness, and urinary incontinence. Such excitement phase dysfunction generally results in dyspareunia. Dyspareunia is thought to affect approximately 40% of women, due

in large part to inadequate lubrication. It has been estimated that over 40 million women will suffer dyspareunia at some time in their lives. On the order of twenty-five million will experience dyspareunia in the peri- and postmenopausal period (see Kelly, S. (1992) *Clinical Practice and Sexuality* 8(8):2 and Sato et al. (1992) *Clinical Practices in Sexuality* 8(5):1). Contemporary symptomatic treatments generally involve the use of physiologically safe lubricants such as egg white, K-Y surgical lubrication jelly (hydroxyethyl-cellulose), Astroglide®, and Replens®. See, for example, Semmens (1974) *Medical Aspects of Human Sexuality* 8:85-86, and Frishmen et al. (1992) *Fertility and Sterility* 58(3):630. When symptomatic treatment fails, pharmacological treatment may be indicated.

[0005] Estrogen therapy is commonly used in the pharmacological treatment of sexual dysfunction in women. Estrogen-based therapies are generally used to increase mucous production, provide vasodilatory effects, or to increase the general health of the vagina. Nadelson et al., eds., *Treatment Interventions in Human Sexuality* (New York: Plenum Press, 1983). In such treatments, estrogen is administered orally, parenterally (e.g., by injection), or topically. With oral administration, the estrogen concentration encountered by the liver is generally four- to five-fold greater than estrogen levels in peripheral blood (the "first pass effect"). This effect may lead to an undesirable increase in the production of certain coagulation factors and renin substrates by the liver. Parenterally administered estrogen avoids the first pass effect in the liver. However, all estrogen-based therapies are known to increase the risk of endometrial hyperplasia endometrial cancer and breast cancer in treated individuals.

[0006] U.S. Patent Nos. 6,469,016, 6,593,313 and 5,877,216 to Place et al. (all assigned to VIVUS, Inc., Mountain View, California) describe methods and formulations for treating sexual dysfunction in women using phosphodiesterase inhibitors, prostaglandins, androgens, and other vasoactive agents, wherein the formulations are administered to an individual's vagina and/or vulvar region. U.S. Patent No. 6,593,369 to Neal (also assigned to VIVUS, Inc.) describes a method and formulation for enhancing female sexual desire and responsiveness using topically administrable prostaglandin compositions. While these methods and formulations have proven to be exceptionally effective, there continues to be a need for improved formulations that provide additional benefits.

SUMMARY OF THE INVENTION

[0007] Accordingly, the present invention is addressed to the aforementioned need in the art, and provides a novel way to enhance female sexual desire and responsiveness, wherein drug administration is on an "as-needed" basis rather than involving chronic pharmacotherapy, and is highly effective in the vast majority of women. The formulations and methods of the invention not only enhance female sexual desire and responsiveness, but are also useful in improving the tissue health of

the female genitalia and preventing vaginal atrophy, preventing pain during intercourse as a result of dyspareunia, and alleviating vaginal itching and dryness associated with dyspareunia and other conditions.

[0008] In one embodiment, an immediate release topical pharmaceutical formulation is provided that comprises: (a) a pharmacologically effective amount of a phosphodiesterase inhibitor, such as a Type III, Type IV, or Type V phosphodiesterase inhibitor; and (b) a pharmaceutically acceptable topical carrier. The topical carrier is selected so as to provides substantially complete (>75%, preferably >90%) release of the phosphodiesterase inhibitor from the formulation upon contact with the body surface (i.e., with the mucosal surface of an individual's vulvar region and/or vagina), i.e., within about 1 minute to about 60 minutes following administration, preferably within about 5 minutes to about 60 minutes following administration. Accordingly, such an immediate release formulation enables "as-needed" administration, i.e., administration at some point just prior to sexual activity, i.e., about 1 minute to about 60 minutes, more about 5 minutes to about 60 minutes, prior to sexual activity. The therapeutically effective dosage of the phosphodiesterase inhibitor will, of course, vary with the particular inhibitor, dosage form, and other factors, but will generally be in the range of about 5 µg to about 125 mg per dose, more typically in the range of about 50 µg to about 50 mg per dose. For creams, gels, ointments, etc., the concentration of the phosphodiesterase inhibitor is generally in the range of about 0.05 wt.% to about 5 wt.%.

[0009] One or more additional active agents, which may or may not be vasoactive agents, are administered along with the phosphodiesterase inhibitor. The active agents may be simultaneously administered, either in the same composition or dosage form or in different compositions or dosage forms, or the different active agents may be administered sequentially. Preferably, the additional active agent or agents are given as a pre-medication, or pre-treatment, topically, orally, or using some other route of administration.

[00010] In another embodiment, the invention provides a method for enhancing sexual desire and responsiveness in women by topically administering the aforementioned formulation, i.e., by administering the formulation to the individual's vulvar region and/or vagina, on an as-needed basis. It will be appreciated that "enhancement of sexual desire and responsiveness" includes the prevention and treatment of individuals prone to or suffering from a sexual dysfunction as well as enhancement of sexual desire and responsiveness in "normal" individuals, i.e., individuals not prone to or suffering from a sexual dysfunction.

[00011] In another embodiment, a packaged kit is provided that includes the pharmaceutical formulation of the invention, a container housing the formulation during storage and prior to administration, and instructions, e.g., written instructions on a package insert or label, for carrying out drug administration in a therapeutically effective manner. The formulation may be packaged in the

form of any topically administrable dosage form, e.g., as a cream, gel, or vaginal suppository containing the phosphodiesterase inhibitor. The dosage form may be a unit dosage form, i.e., a dosage form that contains a unit dosage of the active agent, wherein the unit dosage is a therapeutically effective dosage for the treatment of female sexual dysfunction, and is in the range of about 5 µg to about 125 mg, generally about 50 µg to about 50 mg per dose.

DETAILED DESCRIPTION OF THE INVENTION

[00012] Before describing the present invention in detail, it is to be understood that this invention is not limited to delivery of specific drugs, carriers or use of particular drug delivery systems, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[00013] It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a phosphodiesterase inhibitor" includes not only a single phosphodiesterase inhibitor but also a combination, e.g., a mixture, of two or more phosphodiesterase inhibitors, reference to "a pharmaceutically acceptable carrier" includes a single such carrier as well as a combination, e.g., a mixture, of two or more pharmaceutically acceptable carriers, and the like.

[00014] In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below. In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.

[00015] The terms "active agent" and "pharmacologically active agent" are used interchangeably herein to refer to a chemical compound that induces a desired pharmacological, physiological effect, in this case, treatment of female sexual dysfunction. The primary active agents herein are phosphodiesterase inhibitors. The terms "active agent" and "pharmacologically active agent" also encompass pharmaceutically acceptable, pharmacologically active derivatives of those active agents specifically mentioned herein, including, but not limited to, salts, esters, amides, inclusion complexes, prodrugs, metabolites, analogs, and the like. When the terms "active agent," "pharmacologically active agent," "phosphodiesterase inhibitor," and any other term referring to a specific drug or drug type are used, then, it is to be understood that the active agent *per se* is intended as well as pharmaceutically acceptable, pharmacologically active salts, esters, amides, inclusion complexes, prodrugs, metabolites, analogs, etc.

[00016] "Carriers" or "vehicles" as used herein refer to carrier materials suitable for vulvar and/or vaginal drug administration, and include any such materials known in the art, e.g., any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is nontoxic and does not interact with other components present in the pharmaceutical formulation in a deleterious manner.

[00017] By an "effective" amount, a "pharmacologically effective amount," or a "therapeutically effective amount" of an active agent is meant a nontoxic but sufficient amount of the agent to provide the desired effect of the invention, i.e., enhancement of female sexual dysfunction and responsiveness, including treatment of female sexual dysfunction. The amount that is "effective" will vary from subject to subject, depending on the age and general condition of the individual, the particular active agent or agents, and the like. Thus, it is not always possible to specify an exact "effective amount." However, an appropriate "effective" amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.

[00018] The terms "treating" and "treatment" as used herein refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage. Thus, for example, "treating" sexual dysfunction, as the term is used herein, encompasses both prevention of sexual dysfunction in clinically asymptomatic individuals and treatment of dysfunction in a clinically symptomatic individual. It will be appreciated that "treatment of sexual dysfunction" as the term is used herein includes the treatment of disorders of female sexual desire and/or response, meaning any disorder or dysfunction that causes a decrease in or absence of female sexual responsiveness or female sexual desire. This includes any persistent or recurrent deficiency in the desire for sexual activity. It also includes decreases in the physiological response to sexual stimulation such as slowed or decreased erectile response of the female erectile tissues; slowed, decreased or absent lubrication of the vagina; slowed, decreased, or absent ability to have orgasms; decreased intensity of or pleasure in orgasms; frigidity; sexual aversion; and disorders of female sexual desire and response that are secondary to a general medical condition such as the menopausal or post-menopausal state, radiotherapy of the pelvis, atherosclerosis, pelvic trauma or surgery, peripheral neuropathies, autonomic neuropathies, diabetes mellitus, and disorders of the innervation of any of the sexual organs. Treatment of female sexual dysfunction also includes treatment of substance-induced sexual dysfunction, including but not limited to, decreases in desire and responsiveness secondary to anti-depressants, neuroleptics, anti-hypertensives, tobacco, opiates, alcohol and any other drug found to decrease or eliminate any part of the sexual response cycle. Primary and secondary anorgasmia are included.

[00019] By "pharmaceutically acceptable," such as in the recitation of a "pharmaceutically acceptable carrier," or a "pharmaceutically acceptable acid addition salt," is meant a material that is not biologically or otherwise undesirable, i.e., the material may be incorporated into a pharmaceutical formulation administered to a patient without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the formulation in which it is contained. "Pharmacologically active" (or simply "active") as in a "pharmacologically active" derivative or

metabolite, refers to a derivative or metabolite having the same type of pharmacological activity as the parent compound and approximately equivalent in degree. When the term "pharmaceutically acceptable" is used to refer to a derivative (e.g., a salt) of an active agent, it is to be understood that the compound is pharmacologically active as well, i.e., therapeutically effective for the treatment of premature ejaculation.

[00020] By "as-needed" dosing, also referred to as "*pro re nata*" dosing, "prn" dosing, and "on-demand" dosing or administration, is meant the administration of an active agent at some time prior to anticipated sexual activity and within a time interval sufficient to provide for the desired therapeutic effect, i.e., enhancement in sexual desire and in sexual responsiveness during sexual activity.

Preferably, "as-needed" administration herein does not involve priming doses or chronic administration. As-needed administration will generally be in the range of about 1 minute to about 60 minutes prior to anticipated sexual activity, more typically in the range of about 5 minutes to about 30 minutes prior to anticipated sexual activity.

[00021] The term "immediate release" refers to a formulation that, following topical administration, releases at least 75 wt.%, preferably at least 90 wt.%, of the drug contained therein.

[00022] The term "topical administration" is used in its conventional sense to mean delivery of a topical drug or pharmacologically active agent to the skin or mucosa. Topical administration thus includes transmucosal administration, and transmucosal administration, in the context of the present invention, includes both vulvar administration and vaginal delivery. Vaginal delivery involves direct administration of a pharmaceutical formulation to the vagina of the individual undergoing treatment, and generally involves administration to the distal several centimeters of the vagina.

[00023] The active agent in the present formulations is a phosphodiesterase inhibitor. Exemplary phosphodiesterase inhibitors include, but are not limited to, inhibitors of the type III phosphodiesterases (cAMP-specific-cGMP inhibitable form), the type IV phosphodiesterases (high affinity-high specificity cAMP form) and the type V phosphodiesterases (the cGMP specific form).

[00024] Suitable Type III inhibitors include, but are not limited to, those described in U.S. Patent No. 6,156,753 to Doherty, Jr. et al., assigned to VIVUS, Inc. (Mountain View, CA). Such inhibitors include, by way of example: bipyridines such as milrinone, amrinone and olprinone; imidazolones such as piroximone and enoximone; imidazolines such as imazodan and 5-methyl-imazodan; midazoquinoxalines; dihydropyridazinones such as indolidan and LY181512 (5-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-1,3-dihydro-indol-2-one); dihydroquinolinone compounds such as cilostamide, cilostazol, vesnarinone, and OPC 3911 (N-cyclohexyl-N-hydroxymethyl-4-(2-oxo-1,2-dihydroquinolin-6-yloxy)-butyramide); other compounds such as anagrelide, bemoradan, ibudilast, isomazole, lixazinone, motapizone, olprinone, phthalazinol, pimobendan, quazinone, siguazodan and requinsin; and mixed Type III and Type IV inhibitors such as benafentrine, cis-6-[p-

acetamidophenyl]-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo-[c][1,6]-naphthyridine, EMD 54622 (5-[1-(3,4-dimethoxybenzoyl)-4,4-dimethyl-1,2,3,4-tetrahydrochinolin-6-yl]-6-methyl-3,6-dihydro-1,3,4-thiadiazin-2-one), Org 20241 (N-hydroxy-4-[3,4-dimethoxyphenyl]-thiazole-2-carboximidamide), Org30029 (N-hydroxy-5,6-dimethoxybenzo-[b]-thiophene-2-carboximidamide), saterinone, tolafentrine and zardaverine.

[00025] Suitable Type IV inhibitors include, but are not limited to, those described in U.S. Patent No. 6,127,363 to Doherty, Jr. et al., also assigned to VIVUS, Inc. Examples of Type IV inhibitors that can be administered in conjunction with the present method include, by way of example: pyrrolidinones such as rolipram (4-(3-cyclopentyloxy-4'-methoxyphenyl)-2-pyrrolidinone) and rolipram derivatives such as RO20-1724 (4-(3-butyloxy-4-methoxyphenyl)-imidazolidinone) and RS 33793 (8-(3-nitrophenyl)-6-(3-methyl-2-butenyl)pyrido-[2,3a]pyrazin-5-one); quinazolinones such as niraquazone (3-[3'-nitrophenyl] N-ethylquinazoline-2,6-dione), CP-77059 (1-(carbomethoxyphenyl)-3-benzyl-pyrido[2,3d] pyrimidine-2,4(1H,3H)dione), RS-25344 (1-(3-nitrophenyl)-3-(4-pyridylmethyl)-1,2,3,4-tetrahydro pyrido(2,3-d) pyrimidine-2,4-dione) and other niraquazone analogs; xanthine derivatives such as denbufylline (1,3-di-n-butyl-7-[2'-oxopropyl] xanthine), XT-44 (1-n-butyl-3-n-propylxanthine), arofylline (LAS 31025; 1-propyl-3-(4-chlorophenyl)-xanthine) and BRL 61063; phenyl ethyl pyridines such as CDP 840 (4-(1-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl) pyridine) and compounds disclosed in WO 97/22585 to Guay et al.; tetrahydropyrimidones such as atizoram (CP 80633); diazepine derivatives such as CI 1018 and compounds disclosed in WO 97/36905 to Pascal et al.; oxime carbamates such as filaminast (PDA-641); naphthyridinones such as RS 17597; benzofurans such as 2-butyl-7-methoxy-benzofuran-4-carboxylic acid (3,5-dichloropyridin-4-yl)-amide, 2-benzyl-7-methoxy-benzofuran-4-carboxylic acid (3,5-dichloropyridin-4-yl)-amide, 7-methoxy-2-phenethyl-benzofuran-4-carboxylic acid (3,5-dichloropyridin-4-yl)-amide and 5-(2-butyl-7-methoxy-benzofuran-4-yl)-tetrahydro-pyrimidin-2-one, phenanthridines, such as those disclosed in U.S. Patent No. 6,191,138 to Gutterer; 2-heteroaryl and 2-heterocyclic benzoxazoles, such as those disclosed in U.S. Patent No. 6,166,041 to Cavalla et al.; phenyldihydro-benzofurane compounds such as those disclosed in U.S. Pat. No. 5,902,824 to Ulrich; benzofuran carboxamides as disclosed in U.S. Patent No. 6,211,203 to Amschler et al.; 4-substituted benzofuran compounds such as those disclosed in EP 819688A1; substituted furans as disclosed in Perrier et al. (1999) *Bioorg.Med. Chem. Lett.* 9:323-326 (1999); naphthalene derivatives such as T 440; purine derivatives such as V 112294A and those compounds disclosed in U.S. Patent No. 6,228,859 to Cavalla et al.; cyclohexane carboxylic acids such as ariflo (SB 207499, *c*-4-cyano-4-[3'-cyclopentyloxy-4'-methoxyphenyl]-*r*-1-cyclohexane-carboxylic acid); benzamides such as piclamilast (RP73401; N-(3,5-dichloro-4-pyridyl)-3-cyclopentoxy-4-methoxybenzamide); benzothiophenes such as tibenelast (LY 186655); pyridopyridazinones such as 8-(3-nitrophenyl)-6-


pyridin-4-ylmethyl-6*H*-pyrido[2,3-*d*]pyridazin-5-one; imidazolidinones such as 5-[3-bicyclo[2.2.1]hept-2-ylloxy)-4-methoxyphenyl-1-methyl-imidazolidin-2-one; substituted phenyl compounds, as disclosed in U.S. Pat. No. 5,891,896 to Warrelow et al.; substituted biphenyl compounds as disclosed in U.S. Pat. No. 5,877,190 to Dhainaut et al.; etazolate; and S-(+)-glaucine.

[00026] Examples of type V phosphodiesterase inhibitors include, but are not limited to, pyrazolopyrimidinones, griseolic acid derivatives, 2-phenylpurinone derivatives, phenylpyridone derivatives, fused and condensed pyrimidines, pyrimidopyrimidine derivatives, purine compounds, quinazoline compounds, phenylpyrimidinone derivative, imidazoquinoxalinone derivatives, and other compounds disclosed in WO 96/16644.


[00027] Suitable pyrazolopyrimidinones include, without limitation, 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-*n*-propyl-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-(5-morpholinoacetyl-2-*n*-propoxyphenyl)-1-methyl-3-*n*-propyl-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)-phenyl]-1-methyl-3-*n*-propyl-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-[2-allyloxy-5-(4-methyl-1-piperazinylsulfonyl)-phenyl]-1-methyl-3-*n*-propyl-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-[2-ethoxy-5-[4-(2-propyl)-1-piperazinylsulfonyl]-phenyl]-1-methyl-3-*n*-propyl-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-[2-ethoxy-5-[4-(2-hydroxyethyl)-1-piperazinylsulfonyl]phenyl]-1-methyl-3-*n*-propyl-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-[5-[4-(2-hydroxyethyl)-1-piperazinylsulfonyl]-2-*n*-propoxyphenyl]-1-methyl 1,3-*n*-propyl-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one, 5-[2-ethoxy-5-(4-methyl-1-piperazinylcarbonyl)phenyl]-1-methyl-3-*n*-propyl-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one and 5-[2-ethoxy-5-(1-methyl-2-imidazolyl)phenyl]-1-methyl-3-*n*-propyl-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one.

[00028] Still other type V phosphodiesterase inhibitors useful in conjunction with the invention include: those compounds described in PCT Publication No. WO 01/19802 to Aoyama (Tanabe Seiyaku Co., Ltd.), particularly (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine, 2-(5,6,7,8-tetrahydro-1,7-naphthyridin-7-yl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-morpholinoethyl)carbamoyl]pyrimidine, and (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(1,3,5-trimethyl-4-pyrazolyl)carbamoyl]pyrimidine; zaprinast (1,4-dihydro-5-(2-propoxyphenyl)-7*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-one); 1-(3-chloroanilino)-4-phenylphthalazine (MY5445); dipyridamole, vinpocetine; FR229934 (Fujisawa Pharmaceutical Co., Ltd.); 1-methyl-3-isobutyl-8-(methylamino)xanthine; tadalafil (IC-351; Cialis®); vardenafil (Bayer); 4-aryl-1-isoquinolinone derivatives such as methyl 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate dihydrochloride and the sulfate salt thereof (T-1032); 4-bromo-5-(pyridylmethylamino)-6-[3-(4-chlorophenyl)propoxy]-3(2*H*)pyridazinone; 1-[4-[(1,3-


benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinazolinyl]-4-piperidine-carboxylic acid, monosodium salt; (+)-cis-5,6a,7,9,9a-hexahydro-2-[4-(trifluoromethyl)-phenylmethyl-5-methyl-cyclopent-4,5]imidazo[2,1-b]purin-4(3H)one; furazlocillin; cis-2-hexyl-5-methyl-3,4,5,6a,7,8,9,9a-octahydrocyclopent[4,5]imidazo[2,1-b]purin-4-one; 3-acetyl-1-(2-chlorobenzyl)-2-propylindole-6-carboxylate; 4-bromo-5-(3-pyridylmethylamino)-6-(3-(4-chlorophenyl) propoxy)-3-(2H)pyridazinone; 1-methyl-5-(5-morpholinoacetyl-2-n-propoxyphenyl)-3-n-propyl-1,6-dihydro-7 H-pyrazolo(4,3-d)pyrimidin-7-one; 1-[4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinazolinyl]-4-piperidine carboxylic acid, monosodium salt; Pharmaprojects No. 4516 (Glaxo Wellcome), having the molecular structure




Pharmaprojects No. 5064 (Kyowa Hakko; see WO 96/26940), having the molecular structure



Pharmaprojects No. 5069 (Schering Plough), having the molecular structure



Sch-51866, having the molecular structure



GF-196960 (Glaxo Wellcome); sodium 1-[6-chloro-4-(3, 4-methylenedioxybenzyl)-aminoquinazolin-2-yl]piperidine-4-carboxylate sesquihydrate (E4021); and 6-phenylpyrazolo[3,4-d] pyrimidinones such as 1,3-dimethyl-6(2-propoxy-5-methanesulfonamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one and 1-ethyl-3-methyl-6-(2-propoxy-5-(4-methylthiazol-2-yl)phenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one.

[00029] Particularly preferred Type V phosphodiesterase inhibitors for use in conjunction with the present invention are sildenafil (5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-dipyrimidin-7-one]), tadalafil, vardenafil, zaprinast,

dipyridamole, and the compounds of WO 01/19802 to Aoyama, particularly those identified above.

[00030] Other phosphodiesterase inhibitors include nonspecific inhibitors such as theophylline, theobromine, IBMX, pentoxifylline and papaverine.

[00031] One or more additional active agents can be administered with the phosphodiesterase inhibitor, either simultaneously or sequentially. The additional active agent will generally although not necessarily be one that is effective in treating female sexual dysfunction, and/or an agent that potentiates the effect of the phosphodiesterase inhibitor.

[00032] Such additional active agents, also referred to herein as "secondary" active agents, are generally selected from prostaglandins, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, α -receptor blocking agents (" α -blockers"), β 2-adrenergic agonists, other adrenoreceptor agents, nitrovasodilators, endothelin-derived relaxation factors, muscarinic agents, dopaminergic agonists, opioid antagonists, ergot alkaloids, polypeptide neurotransmitters, agents that stimulate adenylate cyclase, smooth muscle relaxants, calcium channel blockers, leukotriene inhibitors, phosphodiesterase (PDE) inhibitors, steroids, and steroid antagonists and partial

[00033] Suitable prostaglandins may be naturally occurring, semisynthetic, or synthetic. Preferred prostaglandins include, but are not limited to, the naturally occurring prostaglandins PGE₀ (13,14-dihydro-PGE₁), PGE₁, 19-hydroxy-PGE₁, PGE₂, 19-hydroxy-PGE₂, PGA₁, 19-hydroxy-PGA₁, PGA₂, 19-hydroxy-PGA₂, PGB₁, 19-hydroxy-PGB₁, PGB₂, 19-hydroxy-PGB₂, PGB₃, PGD₂, PGF_{1 α} , PGF_{2 α} (dinoprost), PGE₃, PGF_{3 α} , PGI₂ (prostacyclin), and combinations thereof. PGE₀, PGE₁, PGE₂, and the hydrolyzable lower alkyl esters thereof (e.g., the methyl, ethyl and isopropyl esters) are, however, particularly preferred. Other prostaglandins useful in conjunction with the method and formulations of the invention are exemplified, without limitation, by arboprostil, carbaprostacyclin, carboprost tromethamine, dinoprost tromethamine, dinoprostone, enprostil, iloprost, lipoprost, gemeprost, metenoprost, sulprostone, tiaprost, viprostil (CL 115,347), viprostil methyl ester, 16,16-dimethyl- Δ^2 -PGE₁ methyl ester, 15-deoxy-16-hydroxy-16-methyl-PGE₁ methyl ester (misoprostol), 16,16-dimethyl-PGE₁, 11-deoxy-15-methyl-PGE₁, 16-methyl-18,18,19,19-tetrahydrocarbacyclin, 16(RS)-15-deoxy-16-hydroxy-16-methyl-PGE₁ methyl ester, (+)-4,5-didehydro-16-phenoxy- α -tetranor-PGE₂ methyl ester, 11-deoxy-11 α ,16,16-trimethyl-PGE₂, (+)-11 α ,16 α ,16 β -dihydroxy-1,9-dioxo-1-(hydroxymethyl)-16-methyl-trans-prostene, 9-chloro-16,16-dimethyl-PGE₂, 16,16-dimethyl-PGE₂, 15(S)-15-methyl-PGE₂, 9-deoxy-9-methylene-16,16-dimethyl-PGE₂, potassium salt, 19(R)-hydroxy-PGE₂, and 11-deoxy-16,16-dimethyl-PGE₂.

[00034] Angiotensin-converting enzyme ("ACE") inhibitors include, for example, captopril, enalapril, enalaprilat, quinapril, lisinopril, and ramipril. ACE inhibitors may enhance the efficacy of the present formulation and method and decrease long-term complications, such as inflammatory and fibrotic responses.

[00035] Alpha blockers include, but not limited to, prazosin, phentolamine, phenoxybenzamine, dibenamine, doxazosin, terazosin, trimazosin, tolazoline, corynthanine, rauwolscine, piperoxan, alfuzosin, tamsulosin, indoramin, and are especially desirable for increasing the efficacy and prolonging the action of the present method. Other adrenoceptor agents, including but not limited to, yohimbine, labetalol, carvedilol, and bucindolol, may also enhance the activity and prolong the action of the present method.

[00036] Nitrovasodilators include, but are not limited to, nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, amyl nitrate, molsidomine, linsidomine chlorhydrate ("SIN-1"), S-nitroso-N-acetyl-d,l-penicillamine ("SNAP"), S-nitroso-N-glutathione ("SNO-GLU"), erythryl tetranitrate, sodium nitopruside, and the diazenium diolates, or "NONOates." NONOates include, but are not limited to, (Z)-1-{N-methyl-N-[6-(N-methyl-ammoniohexyl)amino]} diazen-1-ium-1,2-diolate ("MAHMA/NO"), (Z)-1-[N-(3-ammoniopropyl)-N-(*n*-propyl)amino] diazen-1-ium-1,2-diolate ("PAPA/NO"), (Z)-1-[N-[3-aminopropyl]-N-[4-(3-aminopropylammonio)butyl]amino] diazen-1-ium-1,2-diolate (spermine NONOate or "SPER/NO") and sodium (Z)-1-(N,N-diethylamino)-diazen-1-ium-1,2-diolate (diethylamine NONOate or "DEA/NO") and derivatives thereof.

[00037] Examples of suitable muscarinic agents are pilocarpine, edrophonium, and bethanacol, and representative dopaminergic agonists are apomorphine and bromocriptine. Opioid antagonists include naloxone, naltrexone, nalmeferine, nalorphine, methyl naltrexone, CTOP diprenorphine, P-funaltrexamine, naloxonazine, norbinaltorphimine, natrindole, BNTX, and other analogs that exhibit opioid antagonistic properties.

[00038] Exemplary ergot alkaloids include ergotamine and ergotamine analogs, e.g., acetergamine, brazergoline, bromerguride, cianergoline, clanegollone, delorgotrile, disulergine, ergonovine maleate, ergotamine tartrate, etisulergine, lergotrile, lysergide, mesulergine, metergoline, metergotamine, nicergoline, pergolide, propisergide, proterguride, and terguride.

[00039] Preferred polypeptide neurotransmitters are vasoactive polypeptide neurotransmitters and include, for example, vasoactive intestinal polypeptide (VIP), VIP agonists (VIP analogs), derivatives of VIP and VIP agonists, particularly hydrolyzable lower alkyl esters, as well as calcitonin, calcitonin gene-related products, cholecystokinin and cholecystokinin analogs (e.g., CCK8). Other suitable secondary agents include: forskolin and water-soluble analogues thereof, which directly stimulate adenylate cyclase; dibutyryl-cyclic AMP; dibutyryl-cyclic GMP; and guanylin.

[00040] The secondary agent is not necessarily, however, a vasoactive agent. For example, the formulations may contain a steroid or a steroid agonist, partial agonist, or antagonist, in addition to the phosphodiesterase inhibitor.

[00041] Steroids will generally be selected from the group consisting of progestins, estrogens, androgens, and combinations thereof. Suitable progestins include, but are not limited to, acetox-

pregnenolone, allylestrenol, anagestone acetate, chlormadinone acetate, cyproterone, cyproterone acetate, desogestrel, dihydrogesterone, dimethisterone, ethisterone (17 α -ethynyltestosterone), ethynodiol diacetate, fluogestone acetate, gestadene, hydroxyprogesterone, hydroxyprogesterone acetate, hydroxyprogesterone caproate, hydroxymethylprogesterone, hydroxymethylprogesterone acetate, 3-ketodesogestrel, levonorgestrel, lynestrenol, medrogestone, medroxyprogesterone acetate, megestrol, megestrol acetate, melengestrol acetate, norethindrone, norethindrone acetate, norethisterone, norethisterone acetate, norethynodrel, norgestimate, norgestrel, norgestrienone, normethisterone, and progesterone. Progesterone, cyproterone acetate, norethindrone, norethindrone acetate, and levonorgestrel are preferred progestins. Suitable estrogens include synthetic and natural estrogens such as: estradiol (i.e., 1,3,5-estratriene-3,17 β -diol, or " β -estradiol") and its esters, including estradiol benzoate, valerate, cypionate, heptanoate, decanoate, acetate and diacetate; 17 α -estradiol; ethynylestradiol (i.e., 17 α -ethynylestradiol) and esters and ethers thereof, including ethynylestradiol 3-acetate and ethynylestradiol 3-benzoate; estriol and estriol succinate; polyestrol phosphate; estrone and its esters and derivatives, including estrone acetate, estrone sulfate, and piperazine estrone sulfate; quinestrol; mestranol; and conjugated equine estrogens. Estradiol and ethynylestradiol are particularly preferred. Suitable androgenic agents include, but are not limited to: the naturally occurring androgens and derivatives thereof, including androsterone, androsterone acetate, androsterone propionate, androsterone benzoate, androstenediol, androstenediol-3-acetate, androstenediol-17-acetate, androstenediol-3,17-diacetate, androstenediol-17-benzoate, androstenediol-3-acetate-17-benzoate, androstenedione, ethylestrenol, oxandrolone, nandrolone phenpropionate, nandrolone decanoate, nandrolone furylpropionate, nandrolone cyclohexane-propionate, nandrolone benzoate, nandrolone cyclohexanecarboxylate, stanozolol, dromostanolone, dromostanolone propionate, testosterone, dehydroepiandrosterone (DHEA; also termed "prasterone"), sodium dehydroepiandrosterone sulfate, 4-dihydrotestosterone (DHT; also termed "stanolone"), and 5 α -dihydrotestosterone; pharmaceutically acceptable esters of testosterone and 4-dihydrotestosterone, typically esters formed from the hydroxyl group present at the C-17 position, including, but not limited to, the enanthate, propionate, cypionate, phenylacetate, acetate, isobutyrate, bucilate, heptanoate, decanoate, undecanoate, caprate and isocaprate esters; and pharmaceutically acceptable derivatives of testosterone such as methyl testosterone, testolactone, oxymetholone and fluoxymesterone. Testosterone and testosterone esters, such as testosterone enanthate, testosterone propionate and testosterone cypionate, are particularly preferred.

[00042] Examples of preferred steroid antagonists or partial agonists are tamoxifen, cenchroman, clomiphene, droloxifene, raloxifene, and pharmaceutically acceptable salts thereof, particularly tamoxifen or clomiphene citrate.

[00043] Particularly desirable secondary active agents are E-series prostaglandins (particularly

PGE₀, PGE₁, PGE₂, and hydrolyzable lower alkyl esters thereof) and phosphodiesterase inhibitors, α -blockers and/or androgenic steroids.

[00044] Any of the active agents may be administered in the form of a salt, ester, amide, inclusion complex, prodrug, metabolite, analog, or other derivative, and such derivatives may be prepared using standard procedures known to those skilled in the art of synthetic organic chemistry and described, for example, by J. March, *Advanced Organic Chemistry: Reactions, Mechanisms and Structure*, 4th Ed. (New York: Wiley-Interscience, 1992). For example, acid addition salts are prepared from an active agent in the form of a free base (typically wherein the neutral form of the drug has a neutral -NH₂ group) using conventional means, involving reaction with a suitable acid. Generally, the base form of the drug is dissolved in a polar organic solvent such as methanol or ethanol and the acid is added thereto. The resulting salt either precipitates or may be brought out of solution by addition of a less polar solvent. Suitable acids for preparing acid addition salts include both organic acids, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, *p*-toluenesulfonic acid, salicylic acid, and the like, as well as inorganic acids, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. An acid addition salt may be reconverted to the free base by treatment with a suitable base. Conversely, preparation of basic salts of acid moieties that may be present on a drug (e.g., the carboxylic acid functionality of prostanoic acid) are prepared in a similar manner using a pharmaceutically acceptable base such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, trimethylamine, or the like. Preparation of esters involves transformation of a carboxylic acid group via a conventional esterification reaction involving nucleophilic attack of an RO⁻ moiety at the carbonyl carbon. Esterification may also be carried out by reaction of a hydroxyl group with an esterification reagent such as an acid chloride. Esters can be reconverted to the free acids, if desired, by using conventional hydrolysis procedures. Amides may be prepared from esters, using suitable amine reactants, or they may be prepared from an anhydride or an acid chloride by reaction with ammonia or a lower alkyl amine.

[00045] Prodrugs and active metabolites may also be prepared using techniques known to those skilled in the art or described in the pertinent literature. Prodrugs are typically prepared by covalent attachment of a moiety that results in a compound that is therapeutically inactive until modified by an individual's metabolic system. Inclusion complexes are complexes formed by interaction of macrocyclic compounds containing an intramolecular cavity of molecular dimensions with the smaller, pharmacologically active agent. Preferred inclusion complexes are formed from α -, β - and γ -cyclodextrins, or from clathrates, in which the "host" molecules form a crystal lattice containing spaces in which "guest" molecules (e.g., the active agent) will fit. See, e.g., Hagan, *Clathrate*

Inclusion Compounds (New York: Reinhold, 1962). Prodrugs, active metabolites, and other derivatives can be prepared using techniques known to those of ordinary skill in the art and/or using syntheses described in the pertinent texts and literature.

[00046] The primary active agent herein, i.e., the phosphodiesterase inhibitor, may be incorporated into and administered in any formulation or dosage form suitable for administration to the vulvar region and/or vagina. If a secondary active agent is also administered topically, it may be incorporated into the same type of formulation or dosage form, either along with the phosphodiesterase inhibitor, or in a separate formulation or dosage form. These formulations and dosage forms will typically contain one or more pharmaceutically acceptable carriers suited to the particular type of formulation, i.e., gel, ointment, suppository, or the like. The carriers are comprised of materials of naturally occurring or synthetic origin that do not adversely affect the active agent or other components of the formulation. Suitable carriers for use herein include water, silicone, waxes, petroleum jelly, polyethylene glycol, propylene glycol, liposomes, sugars such as mannitol and lactose, and a variety of other materials, again depending, on the specific type of formulation used. Pharmaceutical formulations and dosage forms used for administration to the vulvar region and/or vagina are used to deliver drug on an as-needed, on-demand basis, rather than throughout an extended, sustained release profile.

[00047] The formulations used herein may be in the form of an ointment, cream, emulsion, lotion, gel, solid, solution, suspension, foam, or liposomal formulation; such formulations may be used for clitoral, vulvar or vaginal delivery. Alternatively, the formulations may be contained within a vaginal ring, tampon, suppository, sponge, pillow, puff, or osmotic pump system; these platforms are useful solely for vaginal delivery. The dosage form is selected to provide immediate release of the active agent(s), however, so that as-needed administration is possible.

[00048] As is well known in the art, ointments are semisolid preparations that are typically based on petrolatum or other petroleum derivatives. The specific ointment base to be used, as will be appreciated by those skilled in the art, is one that will provide for optimum drug delivery. As with other carriers or vehicles, an ointment base should be inert, stable, nonirritating and nonsensitizing. As explained in *Remington: The Science and Practice of Pharmacy, supra*, at pages 1034-1038, ointment bases may be grouped in four classes: oleaginous bases; emulsifiable bases; emulsion bases; and water-soluble bases. Oleaginous ointment bases include, for example, vegetable oils, fats obtained from animals, and semisolid hydrocarbons obtained from petroleum. Emulsifiable ointment bases, also known as absorbent ointment bases, contain little or no water and include, for example, hydroxystearin sulfate, anhydrous lanolin, and hydrophilic petrolatum. Emulsion ointment bases are either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, and include, for example, cetyl alcohol, glyceryl monostearate, lanolin, and stearic acid. Preferred water-soluble ointment bases are

prepared from polyethylene glycols of varying molecular weight; again, reference may be had to *Remington: The Science and Practice of Pharmacy* for further information.

[00049] Lotions are preparations that may be applied without friction, and are typically liquid or semiliquid preparations in which solid particles, including the active agent, are present in a water or alcohol base. Lotions are usually suspensions of solids, and preferably, for the present purpose, comprise a liquid oily emulsion of the oil-in-water type. It is generally necessary that the insoluble matter in a lotion be finely divided. Lotions will typically contain suspending agents to produce better dispersions as well as compounds useful for localizing the active agent in contact with the skin, e.g., methylcellulose, sodium carboxymethylcellulose, or the like.

[00050] Pharmaceutical emulsion formulations are generally formed from a dispersed phase (e.g., a pharmacologically active agent), a dispersion medium, and an emulsifying agent. If desired, emulsion stabilizers can be included in the formulation as well. A number of pharmaceutically useful emulsions are known in the art, including oil-in-water (o/w) formulations, water-in-oil (w/o) formulations and multiple emulsions such as w/o/w or o/w/o formulations. Emulsifying agents suitable for use in such formulations include, but are not limited to, TWEEN 60®, Span 80®, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate.

[00051] Pharmaceutical creams, are, as known in the art, viscous liquid or semisolid emulsions, either oil-in-water or water-in-oil. Cream bases are water-washable, and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase, also sometimes called the "internal" phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation is generally a nonionic, anionic, cationic, or amphoteric surfactant.

[00052] The above pharmaceutical formulations are formed by dispersing the finely divided or dissolved active agent uniformly throughout the vehicle or base using conventional techniques, typically by a levigating the agent with a small quantity of the base to form a concentrate, which is then diluted geometrically with further base. Alternatively, a mechanical mixer may be used. Creams, lotions, and emulsions are formed by way of a two-phase heat system, wherein oil-phase ingredients are combined under heat to provide a liquified, uniform system. The aqueous-phase ingredients are separately combined using heat. The oil and aqueous phases are then added together with constant agitation and allowed to cool. At this point, concentrated agents may be added as a slurry. Volatile or aromatic materials can be added after the emulsion has sufficiently cooled. Preparation of such pharmaceutical formulations is within the general skill of the art.

[00053] The agent can also be incorporated into a gel formulation using known techniques. Two-phase gel systems generally comprise a suspension or network of small, discrete particles

interpenetrated by a liquid to provide a dispersed phase and a liquid phase. Single-phase gel systems are formed by distributing organic macromolecules uniformly throughout a liquid such that there are no apparent boundaries between the dispersed and liquid phases. Suitable gelling agents for use herein include synthetic macromolecules (e.g., carbomers, polyvinyl alcohols and polyoxyethylene-polyoxypropylene copolymers), gums such as tragacanth, as well as sodium alginate, gelatin, methylcellulose, sodium carboxymethylcellulose, methylhydroxyethyl cellulose and hydroxyethyl cellulose. In order to prepare a uniform gel, dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing or stirring, or combinations thereof.

[00054] Liposomes are microscopic vesicles having a lipid wall comprising a lipid bilayer, and can be used as drug delivery systems herein as well. Generally, liposome formulations are preferred for poorly soluble or insoluble pharmaceutical agents. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium ("DOTMA") liposomes are available under the tradename Lipofectin® (GIBCO BRL, Grand Island, NY). Similarly, anionic and neutral liposomes are readily available as well, e.g., from Avanti Polar Lipids (Birmingham, AL), or can be easily prepared using readily available materials. Such materials include phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline ("DOPC"), dioleoylphosphatidyl glycerol ("DOPG"), and dioleoylphosphatidyl ethanolamine ("DOPE"), among others. These materials can also be mixed with DOTMA in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

[00055] Vaginal suppositories are typically manufactured with polyethylene glycol (PEG), polyethylene oxide and/or other low melting point or water-soluble polymers including fatty acid esters. Suppositories may also be applied to the vulvar region, in which case these dosage forms, which are solid at ambient temperature, rapidly melts when placed on the clitoris and within the vulvar region.

[00056] Typically, formulations and dosage forms for vulvar and/or vaginal administration will contain the phosphodiesterase inhibitor at a concentration such that an effective unit dosage of the active agent is delivered with a single application of the formulation. An effective unit dosage will depend on the phosphodiesterase inhibitor, the dosage form, and other factors, but will generally be in the range of about 5 µg to about 125 mg per dose, more typically in the range of about 50 µg to about 50 mg per dose. In the present formulations, the concentration of the phosphodiesterase inhibitor is generally in the range of about 0.05 wt.% to about 5 wt.%. Since drug dosages typically vary from person to person, however, repeated applications may be used to achieve the desired effect.

[00057] The present formulations and dosage forms may contain one or more pharmaceutically acceptable excipients, i.e., additives that are not pharmacologically active but rather impart some desirable characteristic to the formulations. Suitable excipients are known to those skilled in the art and include, for example, detergents, permeation enhancers, antioxidants, pH-adjusting agents, and buffers. A suitable detergent is one that increases the solubility of the active agent in the formulation or dosage form and therefore the bioavailability of the agent following administration. The detergent will typically be a nonionic, anionic, cationic, or amphoteric surfactant. In the practice of the invention, the surfactant is selected such that local irritation at the site of administration is avoided. Examples of suitable surfactants include Tergitol® and Triton® surfactants (Union Carbide Chemicals and Plastics, Danbury, CT), polyoxyethylene sorbitans, e.g., TWEEN® surfactants (Atlas Chemical Industries, Wilmington, DE), and pharmaceutically acceptable fatty acid esters such as lauryl sulfate and the like. Permeation enhancers are chemical compounds that enhance permeation of the active agent through the body surface, and are useful herein in conjunction with the administration of those active agents that have a relatively low rate of permeation through mucosal membranes. Suitable permeation enhancers include those generally useful in conjunction with topical, transdermal or transmucosal drug delivery. Examples of suitable permeation enhancers include dimethylsulfoxide (DMSO), dimethyl formamide (DMF), N,N-dimethylacetamide (DMA), decylmethylsulfoxide (C₁₀MSO), polyethylene glycol monolaurate (PEGML), glycerol monolaurate, lecithin, the 1-substituted azacycloheptan-2-ones, particularly 1-*n*-dodecylcyclazacycloheptan-2-one (available under the trademark Azone® from Nelson Research & Development Co., Irvine, CA), lower alkanols (e.g., ethanol), SEPA® (available from Macrochem Co., Lexington, MA), and surfactants as discussed above, including, for example, Tergitol®, Nonoxynol-9® and TWEEN-80®.

[00058] The formulation may also include a compound to reduce oxidation of one or more of the components in the formulation. Antioxidants are well known to those skilled in the art. Suitable antioxidants for use in the formulations described herein include butylhydroxytoluene (BHT), ascorbic acid and its sodium and potassium salts, the citrate salts such as sodium, potassium, or ammonium citrate, and tocopherol. The amount of the antioxidant will vary according to the particular antioxidant, amount of the formulation, and other variables. A suitable antioxidantizing amount of an antioxidant for any particular formulation can be determined by one of ordinary skill in the art.

[00059] The formulations and dosage forms may also include one or more pH-adjusting agents. A sufficient amount of a pharmaceutically acceptable acid or base, e.g., HCl or NaOH, may be added to aqueous formulations described herein in order to adjust the pH to the desired value. For nonaqueous formulations, adjusting the pH may be accomplished by adding unit doses of a residual powder obtained by lyophilization of a buffered aqueous solution, e.g., an aqueous solution of a salt of an organic acid, the aqueous solution having the desired pH. Such a buffered aqueous solution may be

advantageously prepared with a citrate salt such as sodium citrate. Upon contact with a mucosal membrane, the lyophilized salt solution will buffer the pH of the mucosal fluid to a pH within the desired range.

[00060] As-needed administration as described herein has several advantages over chronic pharmacologic intervention. First, chronic administration of some agents can result in medical complications. Second, patient compliance can be problematic with a regimented dosing scheme. Furthermore, as-needed administration is convenient and doses are taken only in anticipation of sexual activity. Thus, needless expenditure on wasted dosages is avoided, thereby decreasing the treatment's overall expense.

[00061] The pharmaceutical formulations and dosage forms may be administered vaginally and/or by application to the vulvar region. Often, the formulation will be administered to the clitoris, which is often retracted or hidden under the clitoral hood. Thus, prior to administration, the clitoral hood may be retracted with the finger of one hand, and the clitoral hood should be held back as the dose is applied. Additionally, the formulation may be applied to the tissues covering the clitoris, such as the prepuce and the frenulum of the labia minora, with massaging in order to achieve application to the clitoris.

[00062] The patient treated is typically a woman suffering from some type of sexual dysfunction or disorder, or may possess "normal" sexual desire and/or "normal" sexual responsiveness as those terms are understood defined by clinicians or other experts. For these "normal" women, the present invention offers heightened sexual desire and responsiveness relative to her typical sexual experience, and substantially prevents sexual dysfunction. Usually, however, the female patient seeking enhanced sexual desire and responsiveness suffers from a sexual dysfunction such as a condition, disease, or disorder that affects one of the four stages of the female sexual response: excitement, plateau, orgasm, or resolution. More specifically, the patient may suffer from any one or more of the following:

[00063] a decrease in or absence of female sexual responsiveness or female sexual desire;

[00064] a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity;

[00065] a decrease in the physiological response to sexual stimulation such as, but not limited to, slowed, decreased or absent erectile response of the female erectile tissues; slowed, decrease or absent lubrication of the vagina; slowed decreased or absent ability to reach orgasm, and decreased intensity of or pleasure in orgasms;

[00066] frigidity;

[00067] sexual aversion;

[00068] a condition, disease or disorder that may result in decreased sexual desire and responsiveness including, but not limited to, the menopausal or post-menopausal state, radiotherapy of

the pelvis, multiple sclerosis, atherosclerosis, pelvic trauma or surgery, peripheral neuropathies, autonomic neuropathies, diabetes mellitus, and disorders of the innervation of any of the sexual organs;

[00069] substance-induced decreases in sexual desire and responsiveness including, but not limited to, decreases related to the administration of pharmacologic agents such as, but not limited to, anti-depressants, neuroleptics, anti-hypertensives, opiates, alcohol, and any other agent found to decrease or eliminate any part of the sexual response cycle; and

[00070] primary and secondary anorgasmia.

[00071] In addition to enhancing female sexual desire and responsiveness, the method, formulations, and dosage forms of the invention are useful in improving the tissue health of the female genitalia and preventing vaginal atrophy, preventing pain during intercourse as a result of dyspareunia, and alleviating vaginal itching and dryness associated with dyspareunia and other conditions.

[00072] In another embodiment, a packaged kit is provided that contains: a pharmaceutical formulation of the invention, preferably in a unit dosage form or in a tube or other administration device, or unit dosage form; packaging means for housing the formulation during storage and prior to use; and instructions for carrying out drug administration in a manner effective for the treatment of female sexual dysfunction. The instructions will typically be written instructions on a package insert, a label, and/or on other components of the kit. The kit may contain multiple formulations of different dosages of the same agent, and/or multiple formulations of different active agents.

EXPERIMENTAL:

[00073] The practice of the invention will employ, unless otherwise indicated, conventional techniques of pharmaceutical formulation and the like, which are within the skill of the art. Such techniques are fully explained in the literature. See, for example, *Remington: The Science and Practice of Pharmacy, supra*. In particular, the formulations should be prepared under aseptic conditions. In addition, many formulations, e.g., suppository formulations, are preferably stored in a range from about 3 °C to about 8 °C, and have a melting point preferably in the range from about 15 °C to about 38 °C, more preferably from about 21 °C to about 32 °C. Furthermore, repeated thawing of frozen formulations should be avoided as the formulation may deteriorate or the active agent may become inactivated. Optimally, the formulations will be protected from light.

[00074] In the following examples, efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental error and deviation should be accounted for. Unless indicated otherwise, temperature is in degrees C and pressure is at or near atmospheric pressure at sea level. All reagents were obtained commercially unless otherwise indicated.

EXAMPLE 1

[00075] A cream formulation is prepared for the topical administration of sildenafil. The cream includes the following components:

Sildenafil	500 mg
Beeswax	2.7 g
Carbopol® 934 q.s.	100.0 g

[00076] Mixing is conducted with tile and spatula until a homogeneous cream mixture is obtained having the active agent uniformly dispersed throughout the composition.

EXAMPLE 2

[00077] The procedure of Example 1 is repeated except that the following components are used:

Sildenafil	3.5 g
Polyethylene glycol 400	37.5 g
1,2,6-hexanetriol	20.0 g
Polyethylene glycol 4000 q.s.	100.0 g

[00078] A homogenous cream mixture is obtained.

EXAMPLE 3

[00079] The procedure of Example 1 is repeated except that the following components are used:

Tadalafil	1.0 g
Polyethylene glycol 400	37.0 g
Polyethylene glycol 400 monostearate	26.0 g
Polyethylene glycol 4000 q.s.	100.0 g

[00080] A homogenous cream mixture is obtained.

EXAMPLE 4

[00081] The procedure of Example 1 is repeated except that the following components are used:

TA-1790	2.5 g
Polyethylene glycol 400	47.5 g
Cetyl Alcohol	5.0 g
Polyethylene glycol 4000 q.s.	100.0 g

[00082] A homogenous cream mixture is obtained.

EXAMPLE 5

[00083] A vaginal suppository formulation is prepared for the administration of sildenafil. The suppository includes the following components:

Sildenafil	5.0 g
Polyethylene glycol 400	37.0 g
Glycerol gelatin	20.0 g
Polyethylene glycol 4000 q.s.	100.0 g

[00084] The polyethylene glycol 400 solution containing the active agent is mixed well with glycerol gelatin with a mechanical mixing apparatus and heated to form a liquid. The higher molecular weight polyethylene glycol is added, and the mixture is then cooled in a suppository mold.

EXAMPLE 6

[00085] A vaginal suppository formulation A gel preparation of sildenafil was prepared by admixing 2.5 g sildenafil with 100 g of high purity soybean lecithin (Sigma Chemical Company, St. Louis, MO). Then, water was slowly added with agitation until a thick, viscous gel was produced.

EXAMPLE 7

[00086] A liposomal solution is prepared as follows. Either an aqueous or oil-based solution of tadalafil and an optional additional active agent can be added to a liposomal mixture of, for

example, 10 g of safflower oil, 10 g of soybean oil, 1.2 g of egg phosphatides, and 2.5 g of glycerin in a final volume of 100 ml (the remainder being water). Two mg of tadalafil may be added, and the resulting mixture then stirred until all components are dissolved. Liposomal solutions are particularly favored for active agents with limited solubility in water.

EXAMPLE 8

[00087] Individuals are assessed and pre-screened to assemble an experimental group of subjects suffering from sexual dysfunction. The compositions prepared in Examples 1-7, formulated with various phosphodiesterase inhibitors, are each assessed in the experimental subjects for their ability to increase uterine or vaginal epithelial blood flow. The formulations are applied vaginally, and changes in blood flow or vaginal fluid production after application of the vasodilating formulations are determined using known methods. Increase in vaginal epithelial blood flow is determined using indirect methods such as photoplethysmography (Levin (1980) *Clinics in Obstet. Gynaecol.* 7:213-252), heated oxygen electrode (Wagner et al. (1978), "Vaginal Fluid" in *The Human Vagina*, Evans et al. (eds.), Amsterdam: Elsevier/North Holland Biomedical Press, pp. 121-137), and direct clearance of radioactive Xenon (Wagner et al. (1980) *Obstet. Gynaecol.* 56:621-624). Changes in vulvar blood flow are monitored using laser Doppler velocimetry (Sarrel, P.M. (1990) *Obstet. Gynaecol.* 75:26S-32S).

[00088] Decreased vaginal dryness and/or dyspareunia are negatively correlated with vaginal blood flow rates, wherein increased blood flow to the vagina correlates with increased lubrication and decreased frequency and severity of dyspareunia (Sarrel, P.M. (1990) *Obstet. Gynaecol.* 75:26S-32S). Accordingly, vulvar blood flow after treatment is assessed using laser Doppler velocimetry and compared to baseline levels. Increased vaginal lubrication as a result of treatment with the topical phosphodiesterase inhibitor formulations can also be assessed using the methods of Semmens et al. (1982) *J. Am. Med. Assoc.* 248:445-448. The formulations of Examples 1-7, when assessed using such methods, are found to substantially increase blood flow to the vagina and vulvar area and alleviate vaginal dryness.

WE CLAIM:

1. An as-needed topical pharmaceutical formulation for enhancing sexual desire and responsiveness in a female individual, wherein the formulation comprises: (a) a pharmacologically effective unit dosage of a phosphodiesterase inhibitor selected from Type III phosphodiesterase inhibitors, Type IV phosphodiesterase inhibitors, Type V phosphodiesterase inhibitors, and nonspecific phosphodiesterase inhibitors, wherein the unit dosage is in the range of about 5 μ g to about 125 mg; and (b) a pharmaceutically acceptable topical carrier that provides complete release of the phosphodiesterase inhibitor from the formulation within about 1 minute to about 60 minutes following contact with the mucosal surface of the individual's vulvar region and/or vagina.
2. The formulation of claim 1, wherein the unit dosage is in the range of about 50 μ g to about 50 mg.
3. The formulation of claim 1 or claim 2, wherein the pharmaceutically acceptable topical carrier provides complete release of the phosphodiesterase inhibitor from the formulation within about 5 minute to about 60 minutes following contact with the mucosal surface of the individual's vulvar region and/or vagina.
4. The pharmaceutical formulation of any one of claims 1, 2, or 3, wherein the phosphodiesterase inhibitor is a Type III phosphodiesterase inhibitor.
5. The pharmaceutical formulation of claim 4, wherein the Type III phosphodiesterase inhibitor is selected from the group consisting of bipyridines, imidazolones, imidazolines, dihydropyridazinones, quinolinones, anagrelide, bemoradan, isomazole, lixazinone, pimobendan, siguazodan and trequinsin.
6. The pharmaceutical formulation of claim 5, wherein the Type III phosphodiesterase inhibitor is selected from (5-(4-acetamidophenyl)pyrazin-2-(1H)-one), amrinone, anergrelide, bemoradan, cilostamide, cilostazol, enoximone, imazodan, indolidan, isomazole, lixazinone, 5-methylimazodan, milrinone, pimobendan, piroximone, siguazodan, trequensin, and vesnarinone.
7. The pharmaceutical formulation of any one of claims 1, 2, or 3, wherein the phosphodiesterase inhibitor is a Type IV phosphodiesterase inhibitor.

8. The pharmaceutical formulation of claim 7, wherein the Type IV phosphodiesterase inhibitor is selected from the group consisting of rolipram, 4-(3-butyloxy-4-methoxyphenyl)-imidazolidinone (RO20-1724), nitraquazone, 1-(carbomethoxyphenyl)-3-benzylpyrido[2,3d]pyrimidine-2,4(1H,3H)dione (CP-77059), 1-(3-nitrophenyl)-3-(4-pyridylmethyl)-1,2,3,4-tetrahydro pyrido(2,3-d) pyrimidine-2,4-dione (RS-25344-00), denbufylline, etazolate, 5-[1-(3,4-dimethoxybenzoyl)-4,4-dimethyl-1,2,3,4-tetrahydrochinolin-6-yl]-6-methyl-3,6-dihydro-1,3,4-thiadiazin-2-one (EMD54622), arofylline, and derivatives thereof.

9. The pharmaceutical formulation of any one of claims 1, 2, or 3, wherein the phosphodiesterase inhibitor is a Type V phosphodiesterase inhibitor.

10. The pharmaceutical formulation of claim 8, wherein the Type V phosphodiesterase inhibitor is selected from the group consisting of pyrazolopyrimidinones, griseolic acid derivatives, 2-phenylpurinones, phenylpyridone derivatives, pyrimidines, pyrimidopyrimidines, purines, quinazolines, quinazolinones, quinoxalines, benzimidazoles, cycloheptimidazoles, phenylpyrimidinones, imidazoquinazolines, and imidazoquinoxalinones or aza analogues thereof.

11. The pharmaceutical formulation of claim 10, wherein the Type V phosphodiesterase inhibitor is a pyrazolopyrimidinone.

12. The pharmaceutical formulation of claim 11, wherein the Type V phosphodiesterase inhibitor is selected from sildenafil and acid addition salts thereof.

13. The pharmaceutical formulation of claim 9, wherein the Type V phosphodiesterase inhibitor is tadalafil.

14. The pharmaceutical formulation of claim 9, wherein the Type V phosphodiesterase inhibitor is zaprinast.

15. The pharmaceutical formulation of claim 9, wherein the Type V phosphodiesterase inhibitor is dipyrindamole.

16. The pharmaceutical formulation of claim 9, wherein the Type V phosphodiesterase inhibitor is vardenafil.

17. The pharmaceutical formulation of claim 9, wherein the Type V phosphodiesterase inhibitor is selected from (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine, 2-(5,6,7,8-tetrahydro-1,7-naphthyridin-7-yl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-morpholinoethyl)carbamoyl]pyrimidine, and (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(1,3,5-trimethyl-4-pyrazolyl)carbamoyl]pyrimidine.

18. The pharmaceutical formulation of any one of claims 1, 2, or 3, wherein the phosphodiesterase inhibitor is a nonspecific phosphodiesterase inhibitor.

19. The pharmaceutical formulation of claim 18, wherein the phosphodiesterase inhibitor is selected from the group consisting of theophylline, IBMX, pentoxifylline and papaverine.

20. The pharmaceutical formulation of claim 1, further including an additional active agent.

21. A method for enhancing sexual desire and responsiveness in a female individual, comprising administering the formulation of claim 1 to the individual on an as-needed basis without regular dosing within the context of a chronic dosage regimen.

22. The method of claim 21, wherein the individual is prone to or suffers from a sexual dysfunction.

23. The method of claim 22, wherein the sexual dysfunction is an excitement phase sexual dysfunction.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number
WO 2004/037262 A3

(51) International Patent Classification⁷: **A61K 31/519**,
31/444, 31/4178, 31/4439, A61P 15/12, A61K 31/538,
31/501, 31/4985, 45/08, 31/4704, 31/437, 31/4427, 31/502

(21) International Application Number:
PCT/US2003/033642

(22) International Filing Date: 22 October 2003 (22.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/279,039 22 October 2002 (22.10.2002) US

(71) Applicant: **VIVUS, INC.** [US/US]; 1172 Castro Street,
Mountain View, CA 94040 (US).

(72) Inventors: **PLACE, Virgil, A.**; P.O. Box 44555, 10 Ala
Kahua, Kawaihae, HI 96743 (US). **WILSON, Leland, F.**;
164 East Creek Drive, Menlo Park, CA 94025 (US). **DO-
HERTY, Paul, C.** (deceased). **HANAMOTO, Mark, S.**;
3301 Haskins Drive, Belmont, CA 94002 (US). **SPIVAK,
Alfred, P.**; 360 Arbor Road, Menlo Park, CA 94025 (US).
GESUNDHEIT, Neil; 250 Portola Court, Los Altos, CA
94022 (US). **BENNETT, Sean, R.**; Apartment 2, 816
Cherry Street, Denver, CO 80220 (US).

(74) Agents: **REED, Dianne, E.** et al.; Reed & Eberle LLP, 800
Menlo Avenue, Suite 210, Menlo Park, CA 94025 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
12 August 2004

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION FOR ENHANCEMENT OF FEMALE
SEXUAL DESIRE AND RESPONSIVENESS

(57) Abstract: An immediate release topical pharmaceutical composition is provided which is administrable on an as-needed basis
to enhance female sexual desire and responsiveness. The formulation contains a Type III, Type IV, Type V, or nonspecific phospho-
diesterase inhibitor as an active agent.

WO 2004/037262 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/33642

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/519 A61P15/12 A61K45/08 A61K31/444 A61K31/538
A61K31/4704 A61K31/4178 A61K31/501 A61K31/437 A61K31/4439
A61K31/4985 A61K31/4427 A61K31/502

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 097 706 A (PFIZER LTD ;PFIZER (US)) 9 May 2001 (2001-05-09) paragraphs '0034!', '0067!', '0071!', '0155!', '0332!', '0338!', '0341!', '0344!', '0545!' - '0549!; claims 1,37 -----	1-8, 20-23
X	US 6 251 436 B1 (DRIZEN ALAN ET AL) 26 June 2001 (2001-06-26) claims 1,4 column 4, lines 20-26,35-37 column 5, lines 17-21 column 9, lines 1-19 column 8, lines 58,59 column 11, lines 11,22,31 ----- -/--	1-6, 20-23

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

25 May 2004

Date of mailing of the international search report

24. 05. 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Allnutt, S

INTERNATIONAL SEARCH REPORT

Application No

PCT/US 03/33642

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 02/058703 A (CUTLER NEAL R ;SRAMEK JOHN (US); R T ALAMO VENTURES I LLC (US)) 1 August 2002 (2002-08-01) page 9, lines 8-13 page 25, lines 5,6 page 32, lines 6-8 -----	1-6, 20-23
Y	US 6 187 790 B1 (CUTLER NEAL R) 13 February 2001 (2001-02-13) column 6, lines 4-7; claims 1,11 -----	1-6, 20-23
Y	WO 99/21562 A (VIVUS INC) 6 May 1999 (1999-05-06) cited in the application page 10, lines 11-26; claims 1,15 -----	1-17, 20-23
Y	WO 00/56719 A (SQUIBB BRISTOL MYERS CO) 28 September 2000 (2000-09-28) page 3, lines 1-8 page 51, lines 1,5-7 page 52, lines 27-35 -----	1-3, 9-17, 20-23
Y	US 2002/010198 A1 (SENANAYAKE CHRISANTHA H ET AL) 24 January 2002 (2002-01-24) paragraphs '0074!', '0116!', '0121!'; claims 1,4,9,12 -----	1-3,7,8, 21-23
X	WO 02/34747 A (POLYMERPOULOS EMMANUEL ; EGERLAND UTE (DE); HOEFGEN NORBERT (DE); KRO) 2 May 2002 (2002-05-02) page 5, lines 24,25 page 16, line 18 page 17, lines 1-6 -----	1-3,7, 21-23
X	WO 01/47934 A (NIEWOEHNER ULRICH ; HANING HELMUT (DE); BAYER AG (DE); BISCHOFF ERWIN) 5 July 2001 (2001-07-05) page 16, lines 21,22 page 17, line 25 page 19, line 28 page 20, lines 1-4 -----	1-6, 9-17, 20-23
X	WO 01/44228 A (SANOFI SYNTHELABO ; ALETRU MICHEL (FR); BOVY PHILIPPE R (FR); NAMANE C) 21 June 2001 (2001-06-21) page 21, lines 5,6 page 22, lines 27-33 page 23, lines 21,34 -----	1-3, 9-17, 21-23
X	EP 1 090 644 A (PFIZER PROD INC) 11 April 2001 (2001-04-11) paragraphs '0024!', '0025!'; claims 4,5,9 page 9, lines 23,36,45 -----	20
	----- -/--	

INTERNATIONAL SEARCH REPORT

... nal Application No

PCT/US 03/33642

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/079143 A (COOK ANDREW SIMON ; MIDDLETON DONALD STUART (GB); PRYDE DAVID CAMERON) 10 October 2002 (2002-10-10) claims 14,24 page 12, lines 29,30 page 20, lines 1-4 page 29, line 29	20
X,P	UECKERT S ET AL: "IMMUNOHISTOCHEMICAL PRESENCE OF CYCLIC AMP- AND CYCLIC GMP-PHOSPHODIESTERASE ISOENZYMES IN THE HUMAN CLITORIS" JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 169, no. 4, 26 April 2003 (2003-04-26), page 311, XP009030515 ISSN: 0022-5347 abstract	1,9

INTERNATIONAL SEARCH REPORT

.....national application No.
PCT/US 03/33642

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 21-23
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 21-23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-4, 5, 7, 9, 20-23 (partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
1-17, 20-23
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

Continuation of Box I.1

Although claims 21-23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 21-23

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 1-4,5,7,9, 20-23 (partially)

Present claims 1-4,5,7,9,20-23 relate to compounds defined by reference to a desirable characteristic or property, namely Type III, IV and V Phosphodiesterase Inhibitors.

The claims therefore encompass a very large number of possible compounds which may have this characteristic and a complete search is therefore not possible. The search was carried out on the basis of the functional feature per se as well as the examples cited in the application. The applicants attention is drawn to the fact that some compounds may be already known to treat the diseases/disorders claimed by the applicant but are as yet not identified as PDE Type III, IV and V inhibitors. It should be noted that the substantive examination can only be carried out to the same extent as the search is limited.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/33642

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1097706	A	09-05-2001	AU 7140700 A	17-05-2001
			AU 7140800 A	17-05-2001
			AU 7140900 A	10-05-2001
			AU 7141100 A	10-05-2001
			BR 0005266 A	08-04-2003
			BR 0005276 A	08-04-2003
			BR 0005299 A	15-04-2003
			CA 2323183 A1	08-05-2001
			CA 2323191 A1	08-05-2001
			CA 2323464 A1	08-05-2001
			CA 2324484 A1	08-05-2001
			CN 1320426 A	07-11-2001
			CN 1328824 A	02-01-2002
			CN 1322526 A	21-11-2001
			CZ 20004106 A3	17-04-2002
			CZ 20004107 A3	17-04-2002
			CZ 20004110 A3	17-04-2002
			EP 1097706 A1	09-05-2001
			EP 1097707 A1	09-05-2001
			EP 1097718 A1	09-05-2001
			EP 1097719 A1	09-05-2001
			HU 0004347 A2	28-06-2001
			HU 0004348 A2	28-06-2001
			HU 0004349 A2	28-06-2001
			HU 0004350 A2	28-06-2001
			JP 2001213802 A	07-08-2001
			JP 2001206855 A	31-07-2001
			JP 2001247478 A	11-09-2001
			JP 2001247479 A	11-09-2001
			NO 20005618 A	09-05-2001
			NO 20005661 A	09-05-2001
			NO 20005662 A	09-05-2001
			NZ 508006 A	28-06-2002
			NZ 508007 A	28-06-2002
			NZ 508011 A	28-06-2002
			NZ 508012 A	28-06-2002
			PL 343753 A1	21-05-2001
			PL 343754 A1	21-05-2001
			PL 343755 A1	21-05-2001
			SK 16702000 A3	02-07-2002
			SK 16712000 A3	02-07-2002
			SK 16722000 A3	10-09-2002
			US 6734186 B1	11-05-2004
			ZA 200006374 A	06-05-2002
			ZA 200006375 A	06-05-2002
			ZA 200006376 A	06-05-2002
US 6251436	B1	26-06-2001	US 6036977 A	14-03-2000
			US 5952006 A	14-09-1999
			US 5897880 A	27-04-1999
			AU 5812999 A	27-03-2000
			CA 2342769 A1	16-03-2000
			EP 1112061 A1	04-07-2001
			JP 2002524408 T	06-08-2002
			WO 0013664 A1	16-03-2000
			US 2001022975 A1	20-09-2001
			ZA 200101659 A	18-12-2001
			AU 750321 B2	18-07-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/33642

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6251436	B1		AU 6588198 A	22-10-1998
			CA 2285181 A1	08-10-1998
			EP 0971694 A1	19-01-2000
			JP 2002513410 T	08-05-2002
			WO 9843614 A1	08-10-1998
			AU 748516 B2	06-06-2002
			AU 6053398 A	26-08-1998
			CA 2279982 A1	13-08-1998
			EP 1006998 A1	14-06-2000
			JP 2002511057 T	09-04-2002
			WO 9834592 A1	13-08-1998
			US 2002176892 A1	28-11-2002
			US 6346271 B1	12-02-2002
			US 6120804 A	19-09-2000
			US 6335034 B1	01-01-2002
			US 2002168412 A1	14-11-2002
			AT 236616 T	15-04-2003
			AU 7244696 A	17-04-1997
			CA 2233280 A1	03-04-1997
			DE 69627365 D1	15-05-2003
			DE 69627365 T2	12-02-2004
			EP 0859597 A1	26-08-1998
			ES 2196180 T3	16-12-2003
			US 6007843 A	28-12-1999
			US 6063405 A	16-05-2000
			WO 9711681 A1	03-04-1997
			US 6387407 B1	14-05-2002
			US 6335035 B1	01-01-2002
			US 5716631 A	10-02-1998
			US 5709883 A	20-01-1998
WO 02058703	A	01-08-2002	US 2002147217 A1	10-10-2002
			US 2002143031 A1	03-10-2002
			CA 2435876 A1	01-08-2002
			EP 1355647 A2	29-10-2003
			WO 02058703 A2	01-08-2002
US 6187790	B1	13-02-2001	AU 3780699 A	23-11-1999
			BR 9908716 A	21-11-2000
			CA 2319542 A1	11-11-1999
			EP 1079764 A1	07-03-2001
			JP 2002537231 T	05-11-2002
			WO 9956666 A1	11-11-1999
			US 6541487 B1	01-04-2003
WO 9921562	A	06-05-1999	US 5877216 A	02-03-1999
			AU 740758 B2	15-11-2001
			AU 1125399 A	17-05-1999
			CA 2306837 A1	06-05-1999
			EP 1027057 A1	16-08-2000
			JP 2001520999 T	06-11-2001
			JP 2003212793 A	30-07-2003
			WO 9921562 A1	06-05-1999
			US 2004014761 A1	22-01-2004
			US 2004044080 A1	04-03-2004
			US 2003207852 A1	06-11-2003
			US 6469016 B1	22-10-2002
			US 6294550 B1	25-09-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

Patent Application No

PCT/US 03/33642

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9921562	A		US 6306841 B1	23-10-2001
			US 6472434 B1	29-10-2002
			US 2001051656 A1	13-12-2001
			US 2002013304 A1	31-01-2002
			US 2002099003 A1	25-07-2002
WO 0056719	A	28-09-2000	AU 765128 B2	11-09-2003
			AU 3732700 A	09-10-2000
			CA 2368023 A1	28-09-2000
			CN 1344257 T	10-04-2002
			EP 1165521 A1	02-01-2002
			ID 30182 A	08-11-2001
			JP 2002540102 T	26-11-2002
			WO 0056719 A1	28-09-2000
			US 6316438 B1	13-11-2001
US 2002010198	A1	24-01-2002	US 6339106 B1	15-01-2002
			US 6331571 B1	18-12-2001
			WO 02060424 A2	08-08-2002
			US 2003096792 A1	22-05-2003
			US 2004067957 A1	08-04-2004
			US 2004092481 A1	13-05-2004
			AU 8906201 A	26-03-2002
			CA 2422246 A1	21-03-2002
			EP 1320360 A1	25-06-2003
			WO 0222114 A2	21-03-2002
			AU 772303 B2	22-04-2004
			CA 2341441 A1	02-03-2000
			CZ 20010677 A3	13-02-2002
			EP 1107746 A2	20-06-2001
			HU 0103408 A2	29-05-2002
			ID 28638 A	21-06-2001
			JP 2002523366 T	30-07-2002
			NO 20010943 A	23-04-2001
			NZ 510193 A	26-09-2003
			PL 346843 A1	25-02-2002
			US 2002188029 A1	12-12-2002
			WO 0010551 A2	02-03-2000
			US 2002183281 A1	05-12-2002
			US 2003195261 A1	16-10-2003
			US 6399826 B1	04-06-2002
WO 0234747	A	02-05-2002	DE 10053275 A1	02-05-2002
			AU 2175302 A	06-05-2002
			BR 0114903 A	14-10-2003
			CA 2428468 A1	02-05-2002
			CN 1484644 T	24-03-2004
			CZ 20031146 A3	15-10-2003
			EE 200300166 A	15-08-2003
			WO 0234747 A1	02-05-2002
			EP 1330455 A1	30-07-2003
			HR 20030427 A1	31-08-2003
			HU 0303034 A2	29-12-2003
			NO 20031722 A	14-04-2003
			ZA 200303236 A	31-07-2003
WO 0147934	A	05-07-2001	DE 19962925 A1	28-06-2001
			DE 10003287 A1	02-08-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/33642

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0147934	A		AU 2365001 A	09-07-2001
			CA 2395418 A1	05-07-2001
			WO 0147934 A1	05-07-2001
			EP 1252165 A1	30-10-2002
			JP 2003519153 T	17-06-2003
			US 2003149033 A1	07-08-2003
WO 0144228	A	21-06-2001	AU 2525701 A	25-06-2001
			WO 0144228 A2	21-06-2001
EP 1090644	A	11-04-2001	BR 0004538 A	17-04-2001
			CA 2321378 A1	30-03-2001
			EP 1090644 A2	11-04-2001
			US 6436944 B1	20-08-2002
WO 02079143	A	10-10-2002	BR 0208455 A	02-03-2004
			CA 2437113 A1	10-10-2002
			EE 200300469 A	16-02-2004
			EP 1373192 A1	02-01-2004
			HU 0303624 A2	01-03-2004
			WO 02079143 A1	10-10-2002
			NO 20034299 A	27-11-2003
			US 2003105132 A1	05-06-2003